
Exelixis (EXEL) Stock Forecast & Price Target
Exelixis (EXEL) Analyst Ratings
Bulls say
Exelixis Inc. demonstrates a positive outlook driven by the promising results from the Phase 3 STELLAR-303 trial, wherein zanzalintinib combined with atezolizumab showed statistically significant improvements in overall survival for metastatic colorectal cancer. The strategic collaboration with Natera to utilize the Signatera test for detecting minimal residual disease in the upcoming STELLAR-316 trial further enhances the potential of Exelixis's pipeline, underscoring the company's commitment to innovative cancer treatments. A discounted cash flow analysis estimates Exelixis's firm value at approximately $13.6 billion, reflecting confidence in the future commercial prospects of its drug candidates, particularly zanzalintinib.
Bears say
Exelixis Inc faces significant commercial risks primarily associated with its key product, Cabometyx (cabozantinib), which could impact its revenue generation capabilities. Furthermore, the ongoing clinical programs, particularly those involving zanzalintinib, must yield favorable data; otherwise, investment in these initiatives may not materialize into profitable outcomes. The presence of generic erosion for existing franchises, especially cabozantinib, coupled with potential long-term dilution risks, presents additional challenges that could hinder the company’s financial stability and growth prospects.
This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.
Exelixis (EXEL) Analyst Forecast & Price Prediction
Start investing in Exelixis (EXEL)
Order type
Buy in
Order amount
Est. shares
0 shares